Fierce Pharma | Valisure links 'unstable' Zantac and its ilk to carcinogen buildup, cancer risk

Fierce Pharma released an article titled, "Valisure links 'unstable' Zantac and its ilk to carcinogen buildup, cancer risk." This article highlights the global recalls that resulted from our detection of high levels of a carcinogen in Zantac and its generic copycats.

View the full article via Fierce Pharma here.

Fierce Pharma | Valisure links 'unstable' Zantac and its ilk to carcinogen buildup, cancer risk

February 1, 2021

Fierce Pharma released an article titled, "Valisure links 'unstable' Zantac and its ilk to carcinogen buildup, cancer risk." This article highlights the global recalls that resulted from our detection of high levels of a carcinogen in Zantac and its generic copycats.

View the full article via Fierce Pharma here.

Fierce Pharma | Valisure links 'unstable' Zantac and its ilk to carcinogen buildup, cancer risk

Fierce Pharma released an article titled, "Valisure links 'unstable' Zantac and its ilk to carcinogen buildup, cancer risk." This article highlights the global recalls that resulted from our detection of high levels of a carcinogen in Zantac and its generic copycats.

View the full article via Fierce Pharma here.

Fierce Pharma released an article titled, "Valisure links 'unstable' Zantac and its ilk to carcinogen buildup, cancer risk." This article highlights the global recalls that resulted from our detection of high levels of a carcinogen in Zantac and its generic copycats.

View the full article via Fierce Pharma here.

SIGN UP FOR THE VALISURE NEWSLETTER 

Sign up to stay updated with Valisure announcements, relevant industry news, company updates, and more. 

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.